{"id":25082,"date":"2026-06-23T21:26:00","date_gmt":"2026-06-23T19:26:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=4aed379acaafd5721fcff2b3a494a32c"},"modified":"2026-06-23T21:26:00","modified_gmt":"2026-06-23T19:26:00","slug":"fairjourney-bio-and-abtherx-partner-to-offer-fully-integrated-antibody-discovery","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=25082","title":{"rendered":"FairJourney Bio and AbTherx Partner to Offer Fully Integrated Antibody Discovery"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<i>FairJourney Bio brings AbTherx\u2019s Atlas transgenic mouse technologies in-house, enabling partner programmes to run from immunisation to a developability-assessed lead in one continuous workflow<\/i><\/li>\n<li>\n<i>Partnership announced at BIO International Convention 2026, as FairJourney Bio scales US presence and deepens its San Diego centre of excellence capabilities with newly opened dedicated cryo-EM facility<\/i><\/li>\n<\/ul><p>SAN DIEGO--(BUSINESS WIRE)--FairJourney Bio (\u201cFJBio\u201d), a global antibody discovery expert, has entered a partnership with AbTherx, Inc. to bring transgenic mouse-based antibody discovery in-house. The agreement gives the Company access to AbTherx\u2019s Atlas\u2122 Full Human Diversity (FHD) and Common Light Chain (cLC) mouse technologies, completing a discovery route that partners can now run end to end entirely within FJBio\u2019s integrated workflow.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260623167457\/en\/2837650\/5\/FairJourneyBio-Logo%2BClaim_RGB_NEW_2026.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260623167457\/en\/2837650\/22\/FairJourneyBio-Logo%2BClaim_RGB_NEW_2026.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260623167457\/en\/2837650\/5\/FairJourneyBio-Logo%2BClaim_RGB_NEW_2026.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260623167457\/en\/2837650\/21\/FairJourneyBio-Logo%2BClaim_RGB_NEW_2026.jpg\" \/><\/a><p>\nFrom the partnership, a programme can now move from immunisation through single B-cell screening and optimisation, and on to candidate stability assessment and cell-line development as a single piece of work, run by one team across FJBio\u2019s global sites in Porto (Portugal), Cambridge (UK), and San Diego (USA). The aim is to enable fewer transitions between providers, shorter timelines, and leads that are built to be developed rather than only to bind.<\/p><p>\nThe Atlas\u2122 Mice come from the team behind the HuMAb Mouse<sup>\u00ae<\/sup>, whose technology has given rise to thirteen marketed antibody therapeutics. At FJBio, the Atlas Mice feed into the B-Cell Navigator platform, the Company\u2019s single B-cell screening and developability engine, so that developability is designed into a molecule from the first sequence rather than corrected later.<\/p><p>\nAbTherx\u2019s patent-pending FHD mice were engineered to deliver fully human antibodies with a broad, human-like antibody response by sourcing VH and VK alleles that represent &gt;99% of the expressed human repertoire, and the cLC mice empower the creation of native-structure bi- and multi-specific IgGs that facilitate manufacturability and developability. The Atlas Mice have been validated through multiple independent, head-to-head studies, consistently outperforming legacy platforms. This technical superiority is observed through broader V gene usage, superior hit rates, enhanced antibody diversity and binding profiles, increased epitope coverage and improved hybridoma and B-cell stability.<\/p><p>\nWithin FJBio\u2019s workflow, this range of antibody diversity is carried through single B-cell screening and developability assessment, so that breadth at the source becomes developable, manufacturable leads rather than hits that still need fixing.<\/p><p>\n<b>Dr. Werner Lanthaler, Chief Executive Officer, FairJourney Bio, commented:<\/b> <i>\u201cWe are investing so a partner\u2019s programme can run from immunisation to a developability-assessed lead inside FJBio, without changing hands. Following a molecule under 'one roof' and with one team of scientists increases probabilities of success significantly.\u201d<\/i><\/p><p>\n<i>\u201cThe AbTherx team has spent decades building, refining, and implementing the premier technologies for human antibody discovery \u2013 but even the most sophisticated platform requires knowledge and diligence to reach its full potential,\u201d <\/i><b>said Dan Rohrer, Chief Technology Officer, AbTherx.<\/b> <i>\u201cUniting our proprietary Full Human Diversity and Common Light Chain technologies with FairJourney Bio\u2019s exceptional, quality-driven scientific team creates a powerful synergy. Together, we are perfectly positioned to translate top-tier science into high-performing therapeutic candidates.\u201d<\/i><\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>For further information, please contact:<\/b><br\/><b>FairJourney Bio<\/b><br\/>Alberto Pinto\n<br\/><a  href=\"mailto:apinto@fjbio.com\" rel=\"nofollow\" shape=\"rect\">apinto@fjbio.com<\/a><\/p><p>\n<b>Zyme Communications<\/b><br\/>Lily Jeffery\n<br\/>Email: <a  href=\"mailto:lily.jeffery@zymecommunications.com\" rel=\"nofollow\" shape=\"rect\">lily.jeffery@zymecommunications.com<\/a><br\/>Tel: +44 (0)7891 477 378<\/p>","protected":false},"excerpt":{"rendered":"<p>FairJourney Bio brings AbTherx\u2019s Atlas transgenic mouse technologies in-house, enabling partner programmes to run from immunisation to a developability-assessed lead in one continuous workflow<\/p>\n<p>Partnership announced at BIO International Convention 20&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-25082","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/25082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25082"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/25082\/revisions"}],"predecessor-version":[{"id":25083,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/25082\/revisions\/25083"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}